Revuforj

Product NDC: 73555-502
Requested package NDC: 73555-502-00
11-digit product format: 735550502
Labeler code: 73555
Product ID: 73555-502_76183831-b710-4be2-a6a7-9349dd501830
Type: HUMAN PRESCRIPTION DRUG
Nonproprietary name: revumenib
Dosage form: TABLET, FILM COATED
Route: ORAL
Labeler: Syndax Pharmaceuticals, Inc.
Application: NDA218944
Marketing category: NDA
Marketing start: 2024-11-15
Substance: REVUMENIB CITRATE
Active strength: 160 mg/1
Pharmacologic classes: Menin Inhibitor [EPC], Menin Inhibitors [MoA]
NDC exclude flag: No
Listing certified through: 2027-12-31
Current FDA listing: Yes

Source provenance: Browse the complete Orange Book source catalog · source snapshot 44.

Orange Book products#

Current product rows page 1 of 1 · 3 matching rows.

Application-product, Trade name, Ingredient table
Application-product	Trade name	Ingredient	Strength	Dosage form / route	RLD / RS	Approval date
N218944-001	REVUFORJ	REVUMENIB CITRATE	EQ 25MG BASE	TABLET / ORAL	RLD	2024-11-15
N218944-002	REVUFORJ	REVUMENIB CITRATE	EQ 110MG BASE	TABLET / ORAL	RLD	2024-11-15
N218944-003	REVUFORJ	REVUMENIB CITRATE	EQ 160MG BASE	TABLET / ORAL	RLD, RS	2024-11-15

Orange Book patents#

Current patent rows page 1 of 1 · 15 matching rows.

Application-product, Patent, Expiration table
Application-product	Patent	Expiration	Use code	Coverage / status	Submission date
N218944-001	10683302	2037-06-08		Drug substance, Drug product	2024-12-13
N218944-001	11479557	2037-06-08	U-4045	Drug product	2024-12-13
N218944-001	11479557	2037-06-08	U-4327	Drug product	2024-12-13
N218944-001	12564590	2042-12-18	U-4045	Drug product	2026-03-31
N218944-001	12564590	2042-12-18	U-4327	Drug product	2026-03-31
N218944-002	10683302	2037-06-08		Drug substance, Drug product	2024-12-13
N218944-002	11479557	2037-06-08	U-4045	Drug product	2024-12-13
N218944-002	11479557	2037-06-08	U-4327	Drug product	2024-12-13
N218944-002	12564590	2042-12-18	U-4045	Drug product	2026-03-31
N218944-002	12564590	2042-12-18	U-4327	Drug product	2026-03-31
N218944-003	10683302	2037-06-08		Drug substance, Drug product	2024-12-13
N218944-003	11479557	2037-06-08	U-4045	Drug product	2024-12-13
N218944-003	11479557	2037-06-08	U-4327	Drug product	2024-12-13
N218944-003	12564590	2042-12-18	U-4045	Drug product	2026-03-31
N218944-003	12564590	2042-12-18	U-4327	Drug product	2026-03-31

Orange Book exclusivity#

Current exclusivity rows page 1 of 1 · 12 matching rows.

Application-product, Exclusivity code, Expiration table
Application-product	Exclusivity code	Expiration
N218944-001	NCE	2029-11-15
N218944-001	ODE-502	2031-11-15
N218944-001	ODE-504	2031-11-15
N218944-001	ODE-505	2031-11-15
N218944-002	NCE	2029-11-15
N218944-002	ODE-502	2031-11-15
N218944-002	ODE-504	2031-11-15
N218944-002	ODE-505	2031-11-15
N218944-003	NCE	2029-11-15
N218944-003	ODE-502	2031-11-15
N218944-003	ODE-504	2031-11-15
N218944-003	ODE-505	2031-11-15

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Trade name	Strength	Dosage form / route	RLD / RS	Approval date	Source SHA-256
2026-10-15 13:18:30	2026-09	N218944-001	REVUFORJ	EQ 25MG BASE	TABLET / ORAL	RLD	2024-11-15	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N218944-002	REVUFORJ	EQ 110MG BASE	TABLET / ORAL	RLD	2024-11-15	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N218944-003	REVUFORJ	EQ 160MG BASE	TABLET / ORAL	RLD, RS	2024-11-15	`c2088c7a36db…`
2026-09-14 22:38:34	2026-08	N218944-001	REVUFORJ	EQ 25MG BASE	TABLET / ORAL	RLD	2024-11-15	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N218944-002	REVUFORJ	EQ 110MG BASE	TABLET / ORAL	RLD	2024-11-15	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N218944-003	REVUFORJ	EQ 160MG BASE	TABLET / ORAL	RLD, RS	2024-11-15	`84e616aacf4f…`
2026-08-18 06:07:40	2026-07	N218944-001	REVUFORJ	EQ 25MG BASE	TABLET / ORAL	RLD	2024-11-15	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N218944-002	REVUFORJ	EQ 110MG BASE	TABLET / ORAL	RLD	2024-11-15	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N218944-003	REVUFORJ	EQ 160MG BASE	TABLET / ORAL	RLD, RS	2024-11-15	`caaa826d4ba7…`
2026-02-19 14:30 UTC	2026-02	N218944-001	REVUFORJ	EQ 25MG BASE	TABLET / ORAL	RLD	2024-11-15	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N218944-002	REVUFORJ	EQ 110MG BASE	TABLET / ORAL	RLD	2024-11-15	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N218944-003	REVUFORJ	EQ 160MG BASE	TABLET / ORAL	RLD, RS	2024-11-15	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N218944-001	REVUFORJ	EQ 25MG BASE	TABLET / ORAL	RLD	2024-11-15	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N218944-002	REVUFORJ	EQ 110MG BASE	TABLET / ORAL	RLD	2024-11-15	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N218944-003	REVUFORJ	EQ 160MG BASE	TABLET / ORAL	RLD, RS	2024-11-15	`31067a03dcf5…`
2025-08-23 18:47 UTC	2025-08	N218944-001	REVUFORJ	EQ 25MG BASE	TABLET / ORAL	RLD	2024-11-15	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N218944-002	REVUFORJ	EQ 110MG BASE	TABLET / ORAL	RLD	2024-11-15	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N218944-003	REVUFORJ	EQ 160MG BASE	TABLET / ORAL	RLD, RS	2024-11-15	`6a471c1ec25d…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N218944-001	REVUFORJ	EQ 25MG BASE	TABLET / ORAL	RLD	2024-11-15	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N218944-002	REVUFORJ	EQ 110MG BASE	TABLET / ORAL	RLD	2024-11-15	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N218944-003	REVUFORJ	EQ 160MG BASE	TABLET / ORAL	RLD, RS	2024-11-15	`fd3edfee7708…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N218944-001	REVUFORJ	EQ 25MG BASE	TABLET / ORAL	RLD	2024-11-15	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N218944-002	REVUFORJ	EQ 110MG BASE	TABLET / ORAL	RLD	2024-11-15	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N218944-003	REVUFORJ	EQ 160MG BASE	TABLET / ORAL	RLD, RS	2024-11-15	`b8a1b40f171c…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N218944-001	REVUFORJ	EQ 25MG BASE	TABLET / ORAL	RLD	2024-11-15	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N218944-002	REVUFORJ	EQ 110MG BASE	TABLET / ORAL	RLD	2024-11-15	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N218944-003	REVUFORJ	EQ 160MG BASE	TABLET / ORAL	RLD, RS	2024-11-15	`03ed91905a0d…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N218944-001	REVUFORJ	EQ 25MG BASE	TABLET / ORAL	RLD	2024-11-15	`2680178bc6a6…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N218944-002	REVUFORJ	EQ 110MG BASE	TABLET / ORAL	RLD	2024-11-15	`2680178bc6a6…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N218944-003	REVUFORJ	EQ 160MG BASE	TABLET / ORAL	RLD, RS	2024-11-15	`2680178bc6a6…`
2026-07-26 02:55 UTC · 3 captures of this ZIP	2026-06	N218944-001	REVUFORJ	EQ 25MG BASE	TABLET / ORAL	RLD	2024-11-15	`a50c72e98297…`
2026-07-26 02:55 UTC · 3 captures of this ZIP	2026-06	N218944-002	REVUFORJ	EQ 110MG BASE	TABLET / ORAL	RLD	2024-11-15	`a50c72e98297…`
2026-07-26 02:55 UTC · 3 captures of this ZIP	2026-06	N218944-003	REVUFORJ	EQ 160MG BASE	TABLET / ORAL	RLD, RS	2024-11-15	`a50c72e98297…`

Observed Orange Book patent history#

Patent history page 1 of 3 · 102 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Patent	Expiration	Use code	Coverage / status	Submission date	Source SHA-256
2026-10-15 13:18:30	2026-09	N218944-001	10683302	2037-06-08		Drug substance, Drug product	2024-12-13	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N218944-001	11479557	2037-06-08	U-4327	Drug product	2024-12-13	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N218944-001	11479557	2037-06-08	U-4045	Drug product	2024-12-13	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N218944-001	12564590	2042-12-18	U-4045	Drug product	2026-03-31	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N218944-001	12564590	2042-12-18	U-4327	Drug product	2026-03-31	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N218944-002	10683302	2037-06-08		Drug substance, Drug product	2024-12-13	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N218944-002	11479557	2037-06-08	U-4327	Drug product	2024-12-13	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N218944-002	11479557	2037-06-08	U-4045	Drug product	2024-12-13	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N218944-002	12564590	2042-12-18	U-4327	Drug product	2026-03-31	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N218944-002	12564590	2042-12-18	U-4045	Drug product	2026-03-31	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N218944-003	10683302	2037-06-08		Drug substance, Drug product	2024-12-13	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N218944-003	11479557	2037-06-08	U-4327	Drug product	2024-12-13	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N218944-003	11479557	2037-06-08	U-4045	Drug product	2024-12-13	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N218944-003	12564590	2042-12-18	U-4327	Drug product	2026-03-31	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N218944-003	12564590	2042-12-18	U-4045	Drug product	2026-03-31	`c2088c7a36db…`
2026-09-14 22:38:34	2026-08	N218944-001	10683302	2037-06-08		Drug substance, Drug product	2024-12-13	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N218944-001	11479557	2037-06-08	U-4327	Drug product	2024-12-13	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N218944-001	11479557	2037-06-08	U-4045	Drug product	2024-12-13	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N218944-001	12564590	2042-12-18	U-4045	Drug product	2026-03-31	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N218944-001	12564590	2042-12-18	U-4327	Drug product	2026-03-31	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N218944-002	10683302	2037-06-08		Drug substance, Drug product	2024-12-13	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N218944-002	11479557	2037-06-08	U-4327	Drug product	2024-12-13	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N218944-002	11479557	2037-06-08	U-4045	Drug product	2024-12-13	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N218944-002	12564590	2042-12-18	U-4327	Drug product	2026-03-31	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N218944-002	12564590	2042-12-18	U-4045	Drug product	2026-03-31	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N218944-003	10683302	2037-06-08		Drug substance, Drug product	2024-12-13	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N218944-003	11479557	2037-06-08	U-4327	Drug product	2024-12-13	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N218944-003	11479557	2037-06-08	U-4045	Drug product	2024-12-13	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N218944-003	12564590	2042-12-18	U-4327	Drug product	2026-03-31	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N218944-003	12564590	2042-12-18	U-4045	Drug product	2026-03-31	`84e616aacf4f…`
2026-08-18 06:07:40	2026-07	N218944-001	10683302	2037-06-08		Drug substance, Drug product	2024-12-13	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N218944-001	11479557	2037-06-08	U-4327	Drug product	2024-12-13	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N218944-001	11479557	2037-06-08	U-4045	Drug product	2024-12-13	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N218944-001	12564590	2042-12-18	U-4045	Drug product	2026-03-31	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N218944-001	12564590	2042-12-18	U-4327	Drug product	2026-03-31	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N218944-002	10683302	2037-06-08		Drug substance, Drug product	2024-12-13	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N218944-002	11479557	2037-06-08	U-4327	Drug product	2024-12-13	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N218944-002	11479557	2037-06-08	U-4045	Drug product	2024-12-13	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N218944-002	12564590	2042-12-18	U-4327	Drug product	2026-03-31	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N218944-002	12564590	2042-12-18	U-4045	Drug product	2026-03-31	`caaa826d4ba7…`

Observed Orange Book exclusivity history#

Exclusivity history page 1 of 3 · 117 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Exclusivity code	Expiration	Source SHA-256
2026-10-15 13:18:30	2026-09	N218944-001	NCE	2029-11-15	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N218944-001	ODE-502	2031-11-15	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N218944-001	ODE-504	2031-11-15	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N218944-001	ODE-505	2031-11-15	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N218944-002	NCE	2029-11-15	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N218944-002	ODE-502	2031-11-15	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N218944-002	ODE-504	2031-11-15	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N218944-002	ODE-505	2031-11-15	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N218944-003	NCE	2029-11-15	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N218944-003	ODE-502	2031-11-15	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N218944-003	ODE-504	2031-11-15	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N218944-003	ODE-505	2031-11-15	`c2088c7a36db…`
2026-09-14 22:38:34	2026-08	N218944-001	NCE	2029-11-15	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N218944-001	ODE-502	2031-11-15	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N218944-001	ODE-504	2031-11-15	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N218944-001	ODE-505	2031-11-15	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N218944-002	NCE	2029-11-15	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N218944-002	ODE-502	2031-11-15	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N218944-002	ODE-504	2031-11-15	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N218944-002	ODE-505	2031-11-15	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N218944-003	NCE	2029-11-15	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N218944-003	ODE-502	2031-11-15	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N218944-003	ODE-504	2031-11-15	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N218944-003	ODE-505	2031-11-15	`84e616aacf4f…`
2026-08-18 06:07:40	2026-07	N218944-001	NCE	2029-11-15	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N218944-001	ODE-502	2031-11-15	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N218944-001	ODE-504	2031-11-15	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N218944-001	ODE-505	2031-11-15	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N218944-002	NCE	2029-11-15	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N218944-002	ODE-502	2031-11-15	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N218944-002	ODE-504	2031-11-15	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N218944-002	ODE-505	2031-11-15	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N218944-003	NCE	2029-11-15	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N218944-003	ODE-502	2031-11-15	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N218944-003	ODE-504	2031-11-15	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N218944-003	ODE-505	2031-11-15	`caaa826d4ba7…`
2026-02-19 14:30 UTC	2026-02	N218944-001	NCE	2029-11-15	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N218944-001	ODE-502	2031-11-15	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N218944-001	ODE-504	2031-11-15	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N218944-001	ODE-505	2031-11-15	`011fe1cb6892…`

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

Additional Listing Data#

Finished product: Yes
Brand name base: Revuforj
Listing expiration: 2027-12-31

Active Ingredients#

Ingredient, Strength table
Ingredient	Strength
REVUMENIB CITRATE	160 mg/1

Harmonized UNII identifiers#

UNII identifiers page 1 of 1 · 1 matching rows.

Identifier, FDA.report destination table
Identifier	FDA.report destination
YL4RYN734D	Internal UNII lookup

Harmonized RxCUI identifiers#

RxCUI identifiers page 1 of 1 · 6 matching rows.

Identifier, FDA.report destination table
Identifier	FDA.report destination
2698331	Internal RxNorm lookup
2698337	Internal RxNorm lookup
2698339	Internal RxNorm lookup
2698341	Internal RxNorm lookup
2698343	Internal RxNorm lookup
2698345	Internal RxNorm lookup

Harmonized SPL set identifiers#

SPL set identifiers page 1 of 1 · 1 matching rows.

Identifier, FDA.report destination table
Identifier	FDA.report destination
6eb3cdbc-0e74-477d-82d6-3bb172d3f63f	Available on FDA.report

DailyMed Product Concepts#

Product concept, Relation, Version table
Product concept	Relation	Version	Effective
f9a8e669-e3a4-4514-a5a1-989bfd44f865	Product name	1	20250717

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDC	Product	Description	Form	Quantity	Strength	SPL version
73555-502-00	Revuforj	30 in 1 BOTTLE, PLASTIC	TABLET, FILM COATED	30		5

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDC	Billing unit	Product NDC	DailyMed indexing SPL	SPL version	Effective
73555-502-00	EA - Each	73555-502	248767d0-80a4-480f-97d7-380d323d29af	1	2024-12-10

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDC	Dashboard title	SPL version	Validation	Dashboard ZIP
73555-502	REVUFORJ (REVUMENIB) TABLET, FILM COATED [SYNDAX PHARMACEUTICALS, INC.]	2	Current NDC, 1 package rows	20250426_6eb3cdbc-0e74-477d-82d6-3bb172d3f63f.zip

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
Revuforj	REVUMENIB	Syndax Pharmaceuticals, Inc.	6eb3cdbc-0e74-477d-82d6-3bb172d3f63f	2026-02-04	Boxed warning, Warnings, Adverse reactions	Exact identifier application applno (NDA): 218944 application number: NDA218944 ndc (package): 73555-502-00 ndc (product): 73555-502 ndc11 (package): 73555050200

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUI	RxNorm string	TTY	DailyMed	SPL version
2698337	Revuforj 110 MG Oral Tablet	PSN	6eb3cdbc-0e74-477d-82d6-3bb172d3f63f	5
2698341	Revuforj 160 MG Oral Tablet	PSN	6eb3cdbc-0e74-477d-82d6-3bb172d3f63f	5
2698345	Revuforj 25 MG Oral Tablet	PSN	6eb3cdbc-0e74-477d-82d6-3bb172d3f63f	5
2698331	revumenib 110 MG Oral Tablet	PSN	6eb3cdbc-0e74-477d-82d6-3bb172d3f63f	5
2698339	revumenib 160 MG Oral Tablet	PSN	6eb3cdbc-0e74-477d-82d6-3bb172d3f63f	5
2698343	revumenib 25 MG Oral Tablet	PSN	6eb3cdbc-0e74-477d-82d6-3bb172d3f63f	5
2698337	revumenib 110 MG Oral Tablet [Revuforj]	SBD	6eb3cdbc-0e74-477d-82d6-3bb172d3f63f	5
2698341	revumenib 160 MG Oral Tablet [Revuforj]	SBD	6eb3cdbc-0e74-477d-82d6-3bb172d3f63f	5
2698345	revumenib 25 MG Oral Tablet [Revuforj]	SBD	6eb3cdbc-0e74-477d-82d6-3bb172d3f63f	5
2698331	revumenib 110 MG Oral Tablet	SCD	6eb3cdbc-0e74-477d-82d6-3bb172d3f63f	5
2698339	revumenib 160 MG Oral Tablet	SCD	6eb3cdbc-0e74-477d-82d6-3bb172d3f63f	5
2698343	revumenib 25 MG Oral Tablet	SCD	6eb3cdbc-0e74-477d-82d6-3bb172d3f63f	5
2698337	Revuforj 110 MG Oral Tablet	SY	6eb3cdbc-0e74-477d-82d6-3bb172d3f63f	5
2698341	Revuforj 160 MG Oral Tablet	SY	6eb3cdbc-0e74-477d-82d6-3bb172d3f63f	5
2698345	Revuforj 25 MG Oral Tablet	SY	6eb3cdbc-0e74-477d-82d6-3bb172d3f63f	5
2698331	revumenib 110 MG (as revumenib citrate 146.5 MG) Oral Tablet	SY	6eb3cdbc-0e74-477d-82d6-3bb172d3f63f	5
2698339	revumenib 160 MG (as revumenib citrate 213.2 MG) Oral Tablet	SY	6eb3cdbc-0e74-477d-82d6-3bb172d3f63f	5
2698343	revumenib 25 MG (as revumenib citrate 33.4 MG) Oral Tablet	SY	6eb3cdbc-0e74-477d-82d6-3bb172d3f63f	5

Packages#

Package NDC, 11-digit format, Description table
Package NDC	11-digit format	Description	Marketing start	Sample	Exclude flag	Status
73555-502-00	73555050200	30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (73555-502-00)	2024-11-15	No	No	Current